DI-022 Use and clinical experience of DOLUTEGRAVIR/ABACAVIR/LAMIVUDINA in a tertiary hospital
BackgroundThe new co-formulated drugs for HIV have made great strides in treating the disease and have achieved excellent health outcomes in patients.PurposeTo analyse the use of dolutegravir/abacavir/lamivudine co-formulated (DTG/ABC/3TC) 50 mg/600 mg/300 mg in HIV infected patients and to evaluate...
Gespeichert in:
| Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A122-A122 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A122 |
|---|---|
| container_issue | Suppl 1 |
| container_start_page | A122 |
| container_title | European journal of hospital pharmacy. Science and practice |
| container_volume | 24 |
| creator | Sanchez, S Vicente Naranjo, L Menendez Pulido, M Valderrey Jimenez, MDM Ruiz Soler, JI Garcia de la Rubia Nieto, MA |
| description | BackgroundThe new co-formulated drugs for HIV have made great strides in treating the disease and have achieved excellent health outcomes in patients.PurposeTo analyse the use of dolutegravir/abacavir/lamivudine co-formulated (DTG/ABC/3TC) 50 mg/600 mg/300 mg in HIV infected patients and to evaluate short term effectiveness.Material and methodsA retrospective observational study was conducted in all patients who started DTG/ABC/3TC in our hospital. The variables included were: age, gender, number of previous antiretroviral regimens, patient type (naïve, pretreated), reason for prescription (treatment initiation, switch strategies and virological failure) and viral load (VL) pretreatment and after 4 and 12 weeks.Results33 patients started treatment with DTG/ABC/3TC, and in 3 it was discontinued it. Mean age of the patients was 51 (±13.4) years and 75.7% were men. 81.9% of patients had been previously treated with at least one antiretroviral regimen. Regarding reasons for prescription we found: treatment naïve patients in 18.1%, presence of virologic failure in 15.1% and switch strategies in 66.8%. The switch strategies included 39.5% of prescriptions in order to improve the toxicity and management of comorbidities, 21.3% to avoid drug–drug interactions (mainly with future treatment of hepatitis C), 3% to improve adherence and 3% to avoid enhancing the haematologic toxicity of chemotherapy. Regarding treatment effectiveness: in naïve patients, after 12 weeks of treatment, VL decreased in 3 patients to |
| doi_str_mv | 10.1136/ejhpharm-2017-000640.269 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2552765302</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4317855371</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1002-6496e6779cdc1c55b4658b8ddc14c4fbf8efe689ffa0ee058ef0cc1e9e4e80c23</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhhdRsNT-hwXPaWc_kz3GttZAVChNr0uyndCUNIlJC3rz4h_1l5ha9ehp3hceZpiHEMpgzJjQE9xtm23a7j0OzPcAQEsYc20uyICD9D1jtLz8y0pfk1HXFRkoIQIjhRkQO4s84Pzz_SPpkKbVhrqyqAqXlhRfG2wLrBzSOqez5zhZzRfLcB0tJ-FdOP0OcfgYrZNZ9BTSoqIpPWB7KNL2jW7rrikOaXlDrvK07HD0M4ckuZ-vpg9e_LyIpmHsZQyAe1oajdr3jds45pTKpFZBFmz6Jp3MszzAHHVg8jwFRFB9BecYGpQYgONiSG7Pe5u2fjlid7C7-thW_UnLleK-VgL-pVjgCyF4oE1PiTOV7Xe2aYt9_5BlYE_K7a9ye1Juz8ptr1x8AbXFc_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1873332869</pqid></control><display><type>article</type><title>DI-022 Use and clinical experience of DOLUTEGRAVIR/ABACAVIR/LAMIVUDINA in a tertiary hospital</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Sanchez, S Vicente ; Naranjo, L Menendez ; Pulido, M Valderrey ; Jimenez, MDM Ruiz ; Soler, JI Garcia ; de la Rubia Nieto, MA</creator><creatorcontrib>Sanchez, S Vicente ; Naranjo, L Menendez ; Pulido, M Valderrey ; Jimenez, MDM Ruiz ; Soler, JI Garcia ; de la Rubia Nieto, MA</creatorcontrib><description>BackgroundThe new co-formulated drugs for HIV have made great strides in treating the disease and have achieved excellent health outcomes in patients.PurposeTo analyse the use of dolutegravir/abacavir/lamivudine co-formulated (DTG/ABC/3TC) 50 mg/600 mg/300 mg in HIV infected patients and to evaluate short term effectiveness.Material and methodsA retrospective observational study was conducted in all patients who started DTG/ABC/3TC in our hospital. The variables included were: age, gender, number of previous antiretroviral regimens, patient type (naïve, pretreated), reason for prescription (treatment initiation, switch strategies and virological failure) and viral load (VL) pretreatment and after 4 and 12 weeks.Results33 patients started treatment with DTG/ABC/3TC, and in 3 it was discontinued it. Mean age of the patients was 51 (±13.4) years and 75.7% were men. 81.9% of patients had been previously treated with at least one antiretroviral regimen. Regarding reasons for prescription we found: treatment naïve patients in 18.1%, presence of virologic failure in 15.1% and switch strategies in 66.8%. The switch strategies included 39.5% of prescriptions in order to improve the toxicity and management of comorbidities, 21.3% to avoid drug–drug interactions (mainly with future treatment of hepatitis C), 3% to improve adherence and 3% to avoid enhancing the haematologic toxicity of chemotherapy. Regarding treatment effectiveness: in naïve patients, after 12 weeks of treatment, VL decreased in 3 patients to <20 copies/mL, and 3 achieved undetectable VL. In patients with virological failure, 1 patient achieved <50 copies/mL, 2 patients <20 copies/mL and 2 patients undetectable VL. In the rest of the patients, 11 had undetectable VL, 9 patients <20 copies/mL and only 2 patients had increased VL at week 12.ConclusionDTG/ABC/3TC was used principally in pretreated patients, and switch strategies was the main reason for the prescriptions. In most patients, low or undetectable viral loads were obtained, thus achieving good disease control.References and/or acknowledgementsClinic guide GESIDA2016.Data Sheet TRIUMEQSpanish Medicines Agency.No conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2017-000640.269</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Antiretroviral drugs ; Patients</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A122-A122</ispartof><rights>2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2017 (c) 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2017 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Sanchez, S Vicente</creatorcontrib><creatorcontrib>Naranjo, L Menendez</creatorcontrib><creatorcontrib>Pulido, M Valderrey</creatorcontrib><creatorcontrib>Jimenez, MDM Ruiz</creatorcontrib><creatorcontrib>Soler, JI Garcia</creatorcontrib><creatorcontrib>de la Rubia Nieto, MA</creatorcontrib><title>DI-022 Use and clinical experience of DOLUTEGRAVIR/ABACAVIR/LAMIVUDINA in a tertiary hospital</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundThe new co-formulated drugs for HIV have made great strides in treating the disease and have achieved excellent health outcomes in patients.PurposeTo analyse the use of dolutegravir/abacavir/lamivudine co-formulated (DTG/ABC/3TC) 50 mg/600 mg/300 mg in HIV infected patients and to evaluate short term effectiveness.Material and methodsA retrospective observational study was conducted in all patients who started DTG/ABC/3TC in our hospital. The variables included were: age, gender, number of previous antiretroviral regimens, patient type (naïve, pretreated), reason for prescription (treatment initiation, switch strategies and virological failure) and viral load (VL) pretreatment and after 4 and 12 weeks.Results33 patients started treatment with DTG/ABC/3TC, and in 3 it was discontinued it. Mean age of the patients was 51 (±13.4) years and 75.7% were men. 81.9% of patients had been previously treated with at least one antiretroviral regimen. Regarding reasons for prescription we found: treatment naïve patients in 18.1%, presence of virologic failure in 15.1% and switch strategies in 66.8%. The switch strategies included 39.5% of prescriptions in order to improve the toxicity and management of comorbidities, 21.3% to avoid drug–drug interactions (mainly with future treatment of hepatitis C), 3% to improve adherence and 3% to avoid enhancing the haematologic toxicity of chemotherapy. Regarding treatment effectiveness: in naïve patients, after 12 weeks of treatment, VL decreased in 3 patients to <20 copies/mL, and 3 achieved undetectable VL. In patients with virological failure, 1 patient achieved <50 copies/mL, 2 patients <20 copies/mL and 2 patients undetectable VL. In the rest of the patients, 11 had undetectable VL, 9 patients <20 copies/mL and only 2 patients had increased VL at week 12.ConclusionDTG/ABC/3TC was used principally in pretreated patients, and switch strategies was the main reason for the prescriptions. In most patients, low or undetectable viral loads were obtained, thus achieving good disease control.References and/or acknowledgementsClinic guide GESIDA2016.Data Sheet TRIUMEQSpanish Medicines Agency.No conflict of interest</description><subject>Antiretroviral drugs</subject><subject>Patients</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kE1Lw0AQhhdRsNT-hwXPaWc_kz3GttZAVChNr0uyndCUNIlJC3rz4h_1l5ha9ehp3hceZpiHEMpgzJjQE9xtm23a7j0OzPcAQEsYc20uyICD9D1jtLz8y0pfk1HXFRkoIQIjhRkQO4s84Pzz_SPpkKbVhrqyqAqXlhRfG2wLrBzSOqez5zhZzRfLcB0tJ-FdOP0OcfgYrZNZ9BTSoqIpPWB7KNL2jW7rrikOaXlDrvK07HD0M4ckuZ-vpg9e_LyIpmHsZQyAe1oajdr3jds45pTKpFZBFmz6Jp3MszzAHHVg8jwFRFB9BecYGpQYgONiSG7Pe5u2fjlid7C7-thW_UnLleK-VgL-pVjgCyF4oE1PiTOV7Xe2aYt9_5BlYE_K7a9ye1Juz8ptr1x8AbXFc_g</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>Sanchez, S Vicente</creator><creator>Naranjo, L Menendez</creator><creator>Pulido, M Valderrey</creator><creator>Jimenez, MDM Ruiz</creator><creator>Soler, JI Garcia</creator><creator>de la Rubia Nieto, MA</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201703</creationdate><title>DI-022 Use and clinical experience of DOLUTEGRAVIR/ABACAVIR/LAMIVUDINA in a tertiary hospital</title><author>Sanchez, S Vicente ; Naranjo, L Menendez ; Pulido, M Valderrey ; Jimenez, MDM Ruiz ; Soler, JI Garcia ; de la Rubia Nieto, MA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1002-6496e6779cdc1c55b4658b8ddc14c4fbf8efe689ffa0ee058ef0cc1e9e4e80c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antiretroviral drugs</topic><topic>Patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanchez, S Vicente</creatorcontrib><creatorcontrib>Naranjo, L Menendez</creatorcontrib><creatorcontrib>Pulido, M Valderrey</creatorcontrib><creatorcontrib>Jimenez, MDM Ruiz</creatorcontrib><creatorcontrib>Soler, JI Garcia</creatorcontrib><creatorcontrib>de la Rubia Nieto, MA</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanchez, S Vicente</au><au>Naranjo, L Menendez</au><au>Pulido, M Valderrey</au><au>Jimenez, MDM Ruiz</au><au>Soler, JI Garcia</au><au>de la Rubia Nieto, MA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DI-022 Use and clinical experience of DOLUTEGRAVIR/ABACAVIR/LAMIVUDINA in a tertiary hospital</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2017-03</date><risdate>2017</risdate><volume>24</volume><issue>Suppl 1</issue><spage>A122</spage><epage>A122</epage><pages>A122-A122</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundThe new co-formulated drugs for HIV have made great strides in treating the disease and have achieved excellent health outcomes in patients.PurposeTo analyse the use of dolutegravir/abacavir/lamivudine co-formulated (DTG/ABC/3TC) 50 mg/600 mg/300 mg in HIV infected patients and to evaluate short term effectiveness.Material and methodsA retrospective observational study was conducted in all patients who started DTG/ABC/3TC in our hospital. The variables included were: age, gender, number of previous antiretroviral regimens, patient type (naïve, pretreated), reason for prescription (treatment initiation, switch strategies and virological failure) and viral load (VL) pretreatment and after 4 and 12 weeks.Results33 patients started treatment with DTG/ABC/3TC, and in 3 it was discontinued it. Mean age of the patients was 51 (±13.4) years and 75.7% were men. 81.9% of patients had been previously treated with at least one antiretroviral regimen. Regarding reasons for prescription we found: treatment naïve patients in 18.1%, presence of virologic failure in 15.1% and switch strategies in 66.8%. The switch strategies included 39.5% of prescriptions in order to improve the toxicity and management of comorbidities, 21.3% to avoid drug–drug interactions (mainly with future treatment of hepatitis C), 3% to improve adherence and 3% to avoid enhancing the haematologic toxicity of chemotherapy. Regarding treatment effectiveness: in naïve patients, after 12 weeks of treatment, VL decreased in 3 patients to <20 copies/mL, and 3 achieved undetectable VL. In patients with virological failure, 1 patient achieved <50 copies/mL, 2 patients <20 copies/mL and 2 patients undetectable VL. In the rest of the patients, 11 had undetectable VL, 9 patients <20 copies/mL and only 2 patients had increased VL at week 12.ConclusionDTG/ABC/3TC was used principally in pretreated patients, and switch strategies was the main reason for the prescriptions. In most patients, low or undetectable viral loads were obtained, thus achieving good disease control.References and/or acknowledgementsClinic guide GESIDA2016.Data Sheet TRIUMEQSpanish Medicines Agency.No conflict of interest</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2017-000640.269</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9956 |
| ispartof | European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A122-A122 |
| issn | 2047-9956 2047-9964 |
| language | eng |
| recordid | cdi_proquest_journals_2552765302 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antiretroviral drugs Patients |
| title | DI-022 Use and clinical experience of DOLUTEGRAVIR/ABACAVIR/LAMIVUDINA in a tertiary hospital |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T18%3A30%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DI-022%E2%80%85Use%20and%20clinical%20experience%20of%20DOLUTEGRAVIR/ABACAVIR/LAMIVUDINA%20in%20a%20tertiary%20hospital&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Sanchez,%20S%20Vicente&rft.date=2017-03&rft.volume=24&rft.issue=Suppl%201&rft.spage=A122&rft.epage=A122&rft.pages=A122-A122&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2017-000640.269&rft_dat=%3Cproquest_bmj_p%3E4317855371%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1873332869&rft_id=info:pmid/&rfr_iscdi=true |